0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Invited Commentary—The Safety of Dietary Supplements:  Comment on "Effect of Enzyte on QT and QTc Intervals" FREE

Paul Shekelle, MD
[+] Author Affiliations

Author Affiliation: RAND Health, Santa Monica, California.


Arch Intern Med. 2010;170(15):1404-1405. doi:10.1001/archinternmed.2010.291.
Text Size: A A A
Published online

According to a National Center for Complementary and Alternative Medicine report, in 2007, Americans spent $14.8 billion on “non-vitamin, non-mineral natural products.”1 To put this in context, this is approximately one-third of US out-of-pocket spending for prescription drugs. Dietary supplements are popular with American consumers.

But with popularity comes concerns about safety. In 2003, dietary supplements containing the herb ephedra were pulled from the market amidst concerns that they contributed to cardiovascular deaths among young people.2 Kava-containing dietary supplements have been associated with liver failure, supplements containing red yeast rice and marketed for the control of cholesterol were found to have been adulterated with lovastatin,3,4 and more recently a report from the Government Accounting Office found that 92% of a sample of herbal supplements contained trace amounts of lead and 80% had at least one other contaminant, such as mercury.5

In this issue of the Archives, Phillips and colleagues add to this list of concerns by documenting worrisome electrocardiographic changes in 9 healthy young male subjects given the dietary supplement Enzyte, which is marketed as “the once daily tablet for natural male enhancement” (http://www.enzyte.com/). Enzyte is promoted as containing Gingko biloba, “horny goat weed extract,” Korean ginseng, L-arginine, Tribulus terrestris extract, and 30 mg of niacin and zinc and 15 mg of copper. In specific, Phillips and colleagues, in a double-blind experiment, found prolongation of QT and QTc intervals, a finding which in other populations has been associated with an increased risk of torsades de pointes ventricular tachycardia.

What should physicians and consumers make of this finding? One limitation is that we do not know who uses Enzyte, and thus do not know the degree to which the studied population of young healthy men is representative of the user population, which could be older and sicker. Second, Phillips and colleagues did not conduct their study long enough to be able to assess adverse health outcomes—outcomes that people can feel or experience. The QT/QTc outcome is a proxy outcome for other, serious health outcomes, and whether these would actually occur is not yet established.

Still, Phillips and colleagues' findings must be taken as a signal that there is something potentially lurking beyond our current eyesight regarding the safety of Enzyte. Their conclusion that clinicians should advise their patients to avoid this dietary supplement until more evidence is available seems justified and prudent. Their report adds to the increasingly loud drumbeat of safety concerns about dietary supplements.

What can be done to ensure that consumers are not exposed to dietary supplements that are unsafe? The Dietary Supplement Health and Education Act of 1994 (DSHEA)6 posits that dietary supplements are “presumed safe” until proven to be otherwise. Clearly, the body of evidence accumulated since 1994 indicates that this assumption is no longer in the public interest and needs to be revised. What needs to happen? First, we need to determine what we mean by “safe.” All things have potential risks: excess salt intake is associated with hypertension, water is necessary for life yet too much water intake can cause dangerous hyponatremia, and too much oxygen can cause various lung and eye conditions. So “safe” cannot equal “no risk at all.” How much risk is too much? This is where the “benefit” comes into play. As a primary care physician, I commonly prescribe pharmaceuticals that I know to have risks, sometimes serious risks, but I do so when the evidence supports that the expected benefit (such as the mortality reduction in patients with systolic heart failure treated with angiotensin-converting enzyme inhibitors) exceeds the expected risks (eg, angioedema, renal failure) by a sufficiently large margin indicating that the prescription is appropriate. What is the benefit of taking a dietary supplement? Under the DSHEA,6 dietary supplements cannot claim to treat medical conditions, meaning that Enzyte cannot claim to treat erectile dysfunction. Rather, dietary supplements may only make “structure/function” claims, ergo, Enzyte promotes “male enhancement.” This distinction is probably lost on many if not most consumers. Furthermore, even to promote “male enhancement” implies a biologically active mechanism for the ingredients in Enzyte. I believe that if a biologically active effect is stated, then there needs to be evidence that this is indeed the case. Disturbingly, in many recent rigorous trials of dietary supplements, they have been found to be no more effective than placebo.710 We are left, then, in the situation where evidence of benefit is slim to nonexistent, which then makes any level of risk—even if it is simply a signal and not evidence of the risk itself, as in the case of Enzyte—a sufficient concern to warrant a recommendation against using it.

Second, the public needs better evidence of the benefits as well as the risks of dietary supplements. In the absence of benefit, no risk is acceptable. It is in the interest of the responsible dietary supplement manufacturers to do more to convince the public that their products are safe and effective. When properly performed, such work could rely on the market to reward manufacturers of safe and effective supplements, while driving out the less-responsible manufacturers. Examples abound where consumers are willing to pay more for “quality” if they have confidence in the evidence of that quality. If the dietary supplement manufacturers do not respond to this challenge, the American public will demand federal regulation.

ARTICLE INFORMATION

Correspondence: Dr Shekelle, RAND Health, 1776 Main St, PO Box 2138, Santa Monica, CA 90407-2138 (shekelle@rand.org).

Financial Disclosure: None reported.

National Center for Complimentary and Alternative Medicine, National Institutes of Health,  The use of complementary and alternative medicine in the United States: cost data.  Bethesda, MD2009;http://nccam.nih.gov/news/camstats/costs/costdatafs.htm. Accessed June 4, 2010
Shekelle  PGHardy  MLMorton  SC  et al.  Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003;289 (12) 1537- 1545
PubMed
US Dept of Health and Human Services, US Food and Drug Administration, Consumer advisory: Kava-containing dietary supplements may be associated with severe liver injury.  Washington, DC2002;http://www.fda.gov/food/resourcesforyou/consumers/ucm085482.htm. Accessed June 4, 2010
US Dept of Health and Human Services, US Food and Drug Administration, Red yeast rice.  Washington, DC2007;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm153116.htm. Accessed June 4, 2010
US Government Accountability Office, Herbal Dietary Supplements. Examples of Deceptive or Questionable Marketing Practices and Potentially Dangerous Advice: Testimony Before the Special Committee on Aging.  Washington, DC US Government Accountability Office May26 2010;
 Dietary Supplement Health and Education Act of 1994. Pub L No. 103-417, 108 Stat 4325
Snitz  BEO'Meara  ESCarlson  MC  et al. Ginkgo Evaluation of Memory (GEM) Study Investigators, Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009;302 (24) 2663- 2670
PubMed Link to Article
DeKosky  STWilliamson  JDFitzpatrick  AL  et al. Ginkgo Evaluation of Memory (GEM) Study Investigators, Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008;300 (19) 2253- 2262
PubMed Link to Article
Tice  JAEttinger  BEnsrud  KWallace  RBlackwell  TCummings  SR Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 2003;290 (2) 207- 214
PubMed Link to Article
Taylor  JAWeber  WStandish  L  et al.  Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA 2003;290 (21) 2824- 2830
PubMed Link to Article

Figures

Tables

References

National Center for Complimentary and Alternative Medicine, National Institutes of Health,  The use of complementary and alternative medicine in the United States: cost data.  Bethesda, MD2009;http://nccam.nih.gov/news/camstats/costs/costdatafs.htm. Accessed June 4, 2010
Shekelle  PGHardy  MLMorton  SC  et al.  Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003;289 (12) 1537- 1545
PubMed
US Dept of Health and Human Services, US Food and Drug Administration, Consumer advisory: Kava-containing dietary supplements may be associated with severe liver injury.  Washington, DC2002;http://www.fda.gov/food/resourcesforyou/consumers/ucm085482.htm. Accessed June 4, 2010
US Dept of Health and Human Services, US Food and Drug Administration, Red yeast rice.  Washington, DC2007;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm153116.htm. Accessed June 4, 2010
US Government Accountability Office, Herbal Dietary Supplements. Examples of Deceptive or Questionable Marketing Practices and Potentially Dangerous Advice: Testimony Before the Special Committee on Aging.  Washington, DC US Government Accountability Office May26 2010;
 Dietary Supplement Health and Education Act of 1994. Pub L No. 103-417, 108 Stat 4325
Snitz  BEO'Meara  ESCarlson  MC  et al. Ginkgo Evaluation of Memory (GEM) Study Investigators, Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009;302 (24) 2663- 2670
PubMed Link to Article
DeKosky  STWilliamson  JDFitzpatrick  AL  et al. Ginkgo Evaluation of Memory (GEM) Study Investigators, Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008;300 (19) 2253- 2262
PubMed Link to Article
Tice  JAEttinger  BEnsrud  KWallace  RBlackwell  TCummings  SR Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 2003;290 (2) 207- 214
PubMed Link to Article
Taylor  JAWeber  WStandish  L  et al.  Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA 2003;290 (21) 2824- 2830
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles